{"id":"NCT03618030","sponsor":"Purdue Pharma, Canada","briefTitle":"PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Adult Laboratory Classroom Study to Evaluate the Safety and Efficacy of PRC-063 Compared to Placebo in Adults With ADHD","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-08-21","primaryCompletion":"2019-07-05","completion":"2019-07-05","firstPosted":"2018-08-07","resultsPosted":"2021-07-26","lastUpdate":"2021-07-26"},"enrollment":288,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["ADHD"],"interventions":[{"type":"DRUG","name":"PRC-063 oral capsules","otherNames":[]},{"type":"DRUG","name":"Placebo oral capsules","otherNames":[]}],"arms":[{"label":"Active Treatment","type":"EXPERIMENTAL"},{"label":"Placebo Treatment","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in adults","primaryOutcome":{"measure":"Post-dose PERMP-T (Permanent Measure of Productivity - Total Score) Scores Measured During the Full-day Adult Laboratory Classroom Visit","timeFrame":"Full-day ALC - 13 hours","effectByArm":[{"arm":"Double-Blind Active Treatment","deltaMin":302.9,"sd":3.5},{"arm":"Double-Blind Placebo Treatment","deltaMin":286.6,"sd":3.52}],"pValues":[{"comp":"OG000 vs OG001","p":".0003"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":8,"countries":["United States"]},"refs":{"pmids":["34189995"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":285},"commonTop":["Headache","Decreased Appetite","Insomnia","Upper Respiratory Tract Infection","Irritability"]}}